{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:05Z","timestamp":1791685325350,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":96,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010446","name":"Institute for Basic Science","doi-asserted-by":"crossref","award":["IBS-R001-D2"],"award-info":[{"award-number":["IBS-R001-D2"]}],"id":[{"id":"10.13039\/501100010446","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01097-4","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T23:01:31Z","timestamp":1633474891000},"page":"1729-1747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease"],"prefix":"10.1016","volume":"18","author":[{"given":"Min-Ho","family":"Nam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Ko","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyowon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heeyoung","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo-Wan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Su","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Cheol","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Jin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ryong","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Duk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3555-0980","authenticated-orcid":false,"given":"C. Justin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01097-4_bib1","doi-asserted-by":"crossref","unstructured":"Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harbor perspectives in medicine. 2012;2.","DOI":"10.1101\/cshperspect.a009258"},{"issue":"Suppl 1","key":"10.1007\/s13311-021-01097-4_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1353-8020(09)70004-5","article-title":"L-dopa therapy for Parkinson's disease: past, present, and future","volume":"15","author":"Nagatsua","year":"2009","journal-title":"Parkinsonism Relat Disord."},{"key":"10.1007\/s13311-021-01097-4_bib3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00702-003-0059-x","article-title":"Dopamine receptor agonists in the therapy of Parkinson's disease","volume":"111","author":"Foley","year":"2004","journal-title":"J Neural Transm (Vienna)."},{"issue":"Suppl 11","key":"10.1007\/s13311-021-01097-4_bib4","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/mds.20461","article-title":"Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations","volume":"20","author":"Widnell","year":"2005","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-021-01097-4_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/PPA.S11182","article-title":"Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease","volume":"5","author":"Robottom","year":"2011","journal-title":"Patient Prefer Adherence."},{"key":"10.1007\/s13311-021-01097-4_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1083\/jcb.46.1.173","article-title":"An appraisal of the use of monoamine oxidase as an enzyme marker for the outer membrane of rat liver mitochondria","volume":"46","author":"Greenawalt","year":"1970","journal-title":"J Cell Biol."},{"key":"10.1007\/s13311-021-01097-4_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs."},{"key":"10.1007\/s13311-021-01097-4_bib8","doi-asserted-by":"crossref","unstructured":"Heo JY, Nam MH, Yoon HH, et al. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. Curr Biol. 2020;30:276\u201391 e9.","DOI":"10.1016\/j.cub.2019.11.079"},{"key":"10.1007\/s13311-021-01097-4_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","article-title":"GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease","volume":"20","author":"Jo","year":"2014","journal-title":"Nat Med."},{"key":"10.1007\/s13311-021-01097-4_bib10","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1113\/jphysiol.2014.278754","article-title":"Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition","volume":"592","author":"Yoon","year":"2014","journal-title":"J Physiol."},{"key":"10.1007\/s13311-021-01097-4_bib11","doi-asserted-by":"crossref","unstructured":"Nam MH, Cho J, Kwon DH, et al. Excessive astrocytic GABA causes cortical hypometabolism and impedes functional recovery following subcortical stroke. Cell Reports. 2020;In press.","DOI":"10.1016\/j.celrep.2020.107861"},{"key":"10.1007\/s13311-021-01097-4_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients","volume":"329","author":"Ives","year":"2004","journal-title":"BMJ."},{"key":"10.1007\/s13311-021-01097-4_bib13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01097-4_bib14","doi-asserted-by":"crossref","unstructured":"Park JH, Ju YH, Choi JW, et al. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease. Sci Adv. 2019;5:eaav0316.","DOI":"10.1126\/sciadv.aav0316"},{"key":"10.1007\/s13311-021-01097-4_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo","year":"2004","journal-title":"Pharmacol Res."},{"key":"10.1007\/s13311-021-01097-4_bib16","doi-asserted-by":"crossref","first-page":"6486","DOI":"10.1016\/j.bmc.2015.08.012","article-title":"Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors","volume":"23","author":"Choi","year":"2015","journal-title":"Bioorg Med Chem."},{"key":"10.1007\/s13311-021-01097-4_bib17","doi-asserted-by":"crossref","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"10.1007\/s13311-021-01097-4_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nature protocols."},{"key":"10.1007\/s13311-021-01097-4_bib19","unstructured":"Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates: Academic Press; 1998."},{"key":"10.1007\/s13311-021-01097-4_bib20","doi-asserted-by":"crossref","first-page":"16884","DOI":"10.1523\/JNEUROSCI.3967-11.2011","article-title":"Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease","volume":"31","author":"Sato","year":"2011","journal-title":"J Neurosci."},{"key":"10.1007\/s13311-021-01097-4_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000442891","article-title":"Optogenetic Inhibition of the Subthalamic Nucleus Reduces Levodopa-Induced Dyskinesias in a Rat Model of Parkinson's Disease","volume":"94","author":"Yoon","year":"2016","journal-title":"Stereotact Funct Neurosurg."},{"key":"10.1007\/s13311-021-01097-4_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12868-019-0487-7","article-title":"Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia","volume":"20","author":"Rentsch","year":"2019","journal-title":"BMC Neurosci."},{"key":"10.1007\/s13311-021-01097-4_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainres.2009.09.103","article-title":"Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease","volume":"1306","author":"Kim","year":"2010","journal-title":"Brain research."},{"key":"10.1007\/s13311-021-01097-4_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/acs.jmedchem.8b01527","article-title":"Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy","volume":"62","author":"Choi","year":"2019","journal-title":"J Med Chem."},{"key":"10.1007\/s13311-021-01097-4_bib25","doi-asserted-by":"crossref","unstructured":"Kim S, Indu Viswanath AN, Park JH, et al. Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model. Neuropharmacology. 2020;167:107989.","DOI":"10.1016\/j.neuropharm.2020.107989"},{"key":"10.1007\/s13311-021-01097-4_bib26","doi-asserted-by":"crossref","unstructured":"Choi JW, Kim S, Yoo JS, et al. Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease. Eur J Med Chem. 2021;212:113103.","DOI":"10.1016\/j.ejmech.2020.113103"},{"key":"10.1007\/s13311-021-01097-4_bib27","doi-asserted-by":"crossref","unstructured":"Yoon HH, Park JH, Kim YH, et al. Optogenetic inactivation of the subthalamic nucleus improves forelimb akinesia in a rat model of Parkinson disease. Neurosurgery. 2014;74:533\u201340; discussion 40\u20131.","DOI":"10.1227\/NEU.0000000000000297"},{"key":"10.1007\/s13311-021-01097-4_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuint.2018.11.005","article-title":"Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model","volume":"122","author":"Miyanishi","year":"2019","journal-title":"Neurochem Int."},{"key":"10.1007\/s13311-021-01097-4_bib29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0006-291X(84)91293-2","article-title":"Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase","volume":"120","author":"Chiba","year":"1984","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1007\/s13311-021-01097-4_bib30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson's disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J Parkinsons Dis."},{"key":"10.1007\/s13311-021-01097-4_bib31","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acschemneuro.7b00050","article-title":"Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease","volume":"8","author":"Nam","year":"2017","journal-title":"ACS Chem Neurosci."},{"key":"10.1007\/s13311-021-01097-4_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bmc.2017.11.036","article-title":"Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy","volume":"26","author":"Yeon","year":"2018","journal-title":"Bioorg Med Chem."},{"key":"10.1007\/s13311-021-01097-4_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrn2652","article-title":"Tests to assess motor phenotype in mice: a user's guide","volume":"10","author":"Brooks","year":"2009","journal-title":"Nat Rev Neurosci."},{"key":"10.1007\/s13311-021-01097-4_bib34","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1172\/JCI67569","article-title":"Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure","volume":"123","author":"Cutando","year":"2013","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01097-4_bib35","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1046\/j.1471-4159.1999.0732434.x","article-title":"Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study","volume":"73","author":"Fornai","year":"1999","journal-title":"J Neurochem."},{"key":"10.1007\/s13311-021-01097-4_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jnc.13409","article-title":"Chronic and progressive Parkinson's disease MPTP model in adult and aged mice","volume":"136","author":"Munoz-Manchado","year":"2016","journal-title":"J Neurochem."},{"key":"10.1007\/s13311-021-01097-4_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fnana.2014.00036","article-title":"Three counting methods agree on cell and neuron number in chimpanzee primary visual cortex","volume":"8","author":"Miller","year":"2014","journal-title":"Front Neuroanat."},{"key":"10.1007\/s13311-021-01097-4_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/mds.21751","article-title":"Glial reactions in Parkinson's disease","volume":"23","author":"McGeer","year":"2008","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-021-01097-4_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5607\/en.2018.27.2.77","article-title":"Astrocytes, Microglia, and Parkinson's Disease","volume":"27","author":"Joe","year":"2018","journal-title":"Exp Neurobiol."},{"key":"10.1007\/s13311-021-01097-4_bib40","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1046\/j.1471-4159.1996.67041532.x","article-title":"Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo","volume":"67","author":"Lamensdorf","year":"1996","journal-title":"J Neurochem."},{"key":"10.1007\/s13311-021-01097-4_bib41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/s41593-020-00735-y","article-title":"Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2-production","volume":"23","author":"Chun","year":"2020","journal-title":"Nat Neurosci."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01097-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01097-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:46:44Z","timestamp":1761806804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007687"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01097-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.07.06.190579","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01097-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}